BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28055965)

  • 1. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients.
    Cao S; Jin S; Shen J; Cao J; Zhang H; Meng Q; Wang C; Zhang A; Zhang P; Yu Y
    Oncotarget; 2017 Jan; 8(5):8657-8669. PubMed ID: 28055965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
    Wang C; Jin S; Xu S; Cao S
    Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
    Kamath SS; McCarley DL; Zlotecki RA
    Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Nikolic N
    J Cancer Res Clin Oncol; 2003 Feb; 129(2):114-22. PubMed ID: 12669236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
    Jett JR; Schild SE; Kesler KA; Kalemkerian GP
    Chest; 2013 May; 143(5 Suppl):e400S-e419S. PubMed ID: 23649448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma.
    Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
    Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
    Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
    Kim H; Choi E; Heo MH; Kim JY; Park KU
    Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
    Crvenkova S; Pesevska M
    J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.
    Ludbrook JJ; Truong PT; MacNeil MV; Lesperance M; Webber A; Joe H; Martins H; Lim J
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1321-30. PubMed ID: 12654444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
    Yashiki C; Hirose T; Sugiyama T; Kusumoto S; Shirai T; Ohmori T; Adachi M; Nakamura A
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):245-9. PubMed ID: 20154478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.